Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3.

IF 41.9 1区 医学 Q1 ONCOLOGY Journal of Clinical Oncology Pub Date : 2025-04-01 Epub Date: 2025-02-27 DOI:10.1200/JCO-24-02786
Natasha B Leighl, Nofisat Ismaila, Greg Durm, Narjust Florez, Janet Freeman-Daily, Bruna Pellini, Deebya Raj Mishra, Erin L Schenk, Lecia Sequist, Navneet Singh, Lyudmila Bazhenova
{"title":"Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3.","authors":"Natasha B Leighl, Nofisat Ismaila, Greg Durm, Narjust Florez, Janet Freeman-Daily, Bruna Pellini, Deebya Raj Mishra, Erin L Schenk, Lecia Sequist, Navneet Singh, Lyudmila Bazhenova","doi":"10.1200/JCO-24-02786","DOIUrl":null,"url":null,"abstract":"<p><p>Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the <i>ASCO Guidelines Methodology Manual</i>. ASCO Living Guidelines follow the <i>ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines</i>. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and 2). Updates are published regularly and can be found at <i>https://ascopubs.org/nsclc-non-da-living-guideline</i>.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"e17-e30"},"PeriodicalIF":41.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/JCO-24-02786","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and 2). Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
无驱动改变的IV期非小细胞肺癌治疗:ASCO生活指南,2024.3版。
生活指南是为选定的主题领域制定的,证据迅速发展,促使推荐的临床实践频繁变化。生活指南由一个常设专家小组定期更新,该小组系统地持续审查卫生文献,如ASCO指南方法手册中所述。ASCO生活指南遵循ASCO临床实践指南利益冲突政策实施。生活指南和更新不能取代临床医生的独立专业判断,也不能解释患者之间的个体差异。有关免责声明和其他重要信息,请参见附录(附录1和附录2)。定期发布更新,可在https://ascopubs.org/nsclc-non-da-living-guideline上找到。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Clinical Oncology
Journal of Clinical Oncology 医学-肿瘤学
CiteScore
41.20
自引率
2.20%
发文量
8215
审稿时长
2 months
期刊介绍: The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.
期刊最新文献
Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging. Is It Time to Retire the Unified Cancer of Unknown Primary Concept in the Precision Oncology Era? Can Pathologic Complete Response Serve as a Valid Surrogate End Point? Reply to: Can Pathologic Complete Response Serve as a Valid Surrogate End Point? Reply to: Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1